olaptesed pegol

Olaptesed pegol (NOX-A12) is a PEGylated L-stereoisomer RNA aptamer, also known as a Spiegelmer, that specifically binds and neutralizes the chemokine CXCL12 (stromal cell-derived factor 1, SDF-1). By inhibiting CXCL12, it blocks signaling through its receptors CXCR4 and CXCR7. This disrupts the protective tumor microenvironment in hematologic malignancies such as chronic lymphocytic leukemia (CLL), mobilizing malignant cells into circulation and preventing their homing to protective niches. Olaptesed pegol is being developed primarily for oncology indications including glioblastoma, CLL, multiple myeloma, colorectal cancer, pancreatic cancer, and has orphan drug status for glioblastoma. It is administered intravenously and has shown promising results in combination with other therapies such as bendamustine/rituximab or bevacizumab/radiotherapy[1][3][5][6][7].

Other names

Anti-CXCL12/SDF-1 Spiegelmer